RESCRIPTOR Tablets contain delavirdine mesylate, a synthetic non-nucleoside reverse transcriptase inhibitor (NNRTI) of the human immunodeficiency virus type 1 (HIV-1).
RESCRIPTOR Tablets are indicated for the treatment of HIV-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.
The following should be considered before initiating therapy with RESCRIPTOR in treatment-naive patients. There are insufficient data directly comparing antiretroviral regimens containing RESCRIPTOR with currently preferred 3-drug regimens for initial treatment of HIV. In studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) (currently considered suboptimal) to RESCRIPTOR plus 2 NRTIs, the proportion of patients receiving the regimen containing RESCRIPTOR who achieved and sustained an HIV-1 RNA level <400 copies/mL over 1 year of therapy was relatively low (see DESCRIPTION OF CLINICAL STUDIES).
Resistant virus emerges rapidly when RESCRIPTOR is administered as monotherapy. Therefore, RESCRIPTOR should always be administered in combination with other antiretroviral agents.
Media Articles Related to Rescriptor (Delavirdine)
Acute HIV infection: Symptoms, diagnosis, and management
Source: HIV / AIDS News From Medical News Today [2017.03.11]
How is acute HIV infection diagnosed, what are the causes, and what is the outlook? How can an acute HIV infection be managed and can it be prevented?
HIV rash: What does it look like and how long does it last?
Source: HIV / AIDS News From Medical News Today [2017.02.22]
Rashes are one of the earliest symptoms of an HIV infection. Learn about the types of rash that can occur, their duration, and treatment options.
Published Studies Related to Rescriptor (Delavirdine)
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. 
OBJECTIVE: Delavirdine is a non-nucleoside reverse transcriptase inhibitor used in combination regimens for the treatment of HIV-1 infection. Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies... CONCLUSIONS: Delavirdine disposition exhibits nonlinear pharmacokinetics and large interpatient variability, and is significantly altered by time of day (impacting potential therapeutic drug monitoring and future pharmacokinetic study designs). Although race and sex appear to influence delavirdine pharmacokinetics, men and women and patients of different races should receive similar mg/kg dosage regimens. The presence of large interpatient variability supports the further investigation of the utility of therapeutic drug monitoring for delavirdine, if target drug concentrations can be better defined.
Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. [2003.02]
To determine the impact of gastric hypoacidity and acidic beverages on delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched subjects with (n = 11) and without (n = 10) gastric hypoacidity received delavirdine 400 mg tid with either water or an acidic beverage (usually orange juice)...
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. [2003.01]
AIMS: To evaluate the safety and the pharmacokinetic interaction between amprenavir and delavirdine after multiple dose administration in healthy volunteers... CONCLUSIONS: Amprenavir is an effective inducer of delavirdine metabolism, probably through its effect on hepatic CYP3A4. This could have consequences in other drug-drug interaction situations. Delavirdine is an inhibitor of amprenavir metabolism. The regimen of amprenavir 600 mg and delavirdine 600 mg twice a day is not recommended when an antiretroviral effect from delavirdine is required.
A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. [2001.03]
CONCLUSION: The use of antiretroviral agents that pharmacokinetically boost saquinavir levels has a modest benefit in saquinavir-experienced patients.
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. [2000.11]
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12.
Clinical Trials Related to Rescriptor (Delavirdine)
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients [Completed]
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies [Completed]
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate
(Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected
children and babies. This study also examines how the body processes Rescriptor when taken
with 2 NRTIs.
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients [Completed]
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in
combination with two or three other drugs to HIV-infected patients. The drugs to be used in
combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients [Completed]
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus
indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients [Withdrawn]
To compare the long-term virologic response to combination therapy with two protease
inhibitors, i. e., nelfinavir (NFV) + saquinavir soft gel capsule (SQVsgc) and delavirdine
(DLV) or combination lamivudine/zidovudine (3TC/ZDV, Combivir) versus NFV and 3TC/ZDV, in
the proportion of patients demonstrating virologic success (< 500 copies/ml HIV RNA) at week
48, without prior virologic or clinical failure. To evaluate the safety and tolerance of
combination protease inhibitors.
To evaluate the durability of virologic response as assessed by the Roche Ultra Sensitive
assay (< 200 copies/ml) and culturable virus. To compare time to a confirmed virologic
response (two consecutive plasma HIV RNA levels < 500 copies/ml) or to a confirmed treatment
relapse following a confirmed virologic response across the treatment arms. To evaluate
biologic phenotype (non-syncytium inducing versus syncytium inducing capacity) and the
evolution and patterns of viral resistance among patients with confirmed treatment failures
at or after weeks 16 to 24. To compare immunologic benefits, as measured by longitudinal
CD4/CD8 cell count profiles. To evaluate the influence of baseline virologic and immunologic
parameters on the magnitude and duration of plasma HIV RNA response. To compare virologic
response between the two dose schedules of NFV and SQVsgc (bid vs tid) and between NFV and
SQVsgc with either DLV or combination 3TC/ZDV. To evaluate compliance and exploratory
Past studies have shown that combination therapies not only will result in better clinical
outcomes but may prolong the effects of therapy. The enhanced effects seen with combination
therapies are likely related to a greater suppression of HIV replication and alterations in
resistance patterns. Both in vitro and in vivo studies suggest that triple-drug therapy may
have an advantage over one- and two-drug regimens. Therefore, triple-drug therapy appears to
be an important strategy in the treatment of HIV infection.